Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Christina Meeks"'
Autor:
Anastasia Lyon, Rakshamani Tripathi, Christina Meeks, Daheng He, Yuanyuan Wu, Jinpeng Liu, Chi Wang, Jing Chen, Haining Zhu, Sujata Mukherjee, Saptadwipa Ganguly, Rina Plattner
Publikováno v:
Cancers, Vol 15, Iss 3, p 954 (2023)
Melanomas harboring NRAS mutations are a particularly aggressive and deadly subtype. If patients cannot tolerate or the melanomas are insensitive to immune checkpoint blockade, there are no effective 2nd-line treatment options. Drugs targeting the RA
Externí odkaz:
https://doaj.org/article/871a5cfedfa548e3aaba0d81896b5572
Autor:
Rakshamani Tripathi, Zulong Liu, Aditi Jain, Anastasia Lyon, Christina Meeks, Dana Richards, Jinpeng Liu, Daheng He, Chi Wang, Marika Nespi, Andrey Rymar, Peng Wang, Melissa Wilson, Rina Plattner
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
Resistance to BRAF/MEK inhibitors is a major impediment to long-term survival for patients with BRAF-mutant melanomas. Here, the authors show that ABL kinases drive resistance by promoting MEK/ERK reactivation and the FDA-approved ABL kinase inhibito
Externí odkaz:
https://doaj.org/article/7126349dcc164a17b73b14d99a4c497c
Autor:
Daheng He, Marika Nespi, Zulong Liu, Christina Meeks, Anastasia Lyon, Jinpeng Liu, Andrey Rymar, Peng Wang, Chi Wang, Rina Plattner, Melissa Wilson, Aditi Jain, Rakshamani Tripathi, Dana Richards
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
Nature Communications
Nature Communications
Metastatic melanoma remains an incurable disease for many patients due to the limited success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic burden for patients with melanomas harboring BRAF mutations; however, most eventu